StoxCipla vs Lupin: share price & financials comparison
NSE: CIPLA vs LUPIN · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Cipla vs Lupin at a glance
Cipla (CIPLA) has a market capitalisation of ₹1,12,437 Cr, against ₹90,559 Cr for Lupin (LUPIN). Over the past year Lupin has returned -0.8%, compared with -7.4% for Cipla. On valuation, Lupin trades at a lower P/E of 17.4 versus 38.8. Lupin earns a higher return on equity (21.6% vs 8.2%). Cipla comes out ahead on valuation, financial health and technicals. Lupin comes out ahead on size, profitability and growth. Across the scored metrics below, Cipla leads on 7 and Lupin on 11. On StoxGud's 10-point checklist, Cipla scores 7/10 and Lupin scores 6/10.
| Metric | Cipla | Lupin |
|---|---|---|
| Size | ||
| Market cap | ₹1,12,437 Cr | ₹90,559 Cr |
| Revenue (latest FY) | ₹28,163 Cr | ₹27,958 Cr |
| Net profit (latest FY) | ₹3,879 Cr | ₹5,333 Cr |
| Valuation | ||
| P/E | 38.8 | 17.4 |
| P/B | 3.18 | 3.77 |
| Dividend yield | 1.15% | 0.61% |
| Profitability | ||
| Return on equity | 8.2% | 21.6% |
| Net profit margin | 10.3% | 16.9% |
| Operating margin | 17.0% | 30.1% |
| Growth | ||
| Revenue growth (YoY) | -2.4% | +11.1% |
| Net profit growth (YoY) | -35.1% | -21.8% |
| Revenue CAGR (multi-year) | +8.0% | +13.0% |
| Financial health | ||
| Debt to equity | 0.01 | 0.23 |
| Momentum | ||
| 1-month return | +4.7% | +1.4% |
| 1-year return | -7.4% | -0.8% |
| 3-year CAGR | +3.9% | +19.1% |
| 5-year CAGR | +8.2% | +16.0% |
| 10-year CAGR | +9.7% | +3.2% |
| Distance from 52W high | -9.4% | -21.3% |
| Technicals | ||
| RSI (14) | 68 | 61 |
| Price vs 200-day avg | +2.1% | -11.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Cipla | Lupin |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✓ | ✗ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 7/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Cipla or Lupin?
Cipla has a market cap of ₹1,12,437 Cr and Lupin has a market cap of ₹90,559 Cr as of 13 Nov 2026.
Which has a lower P/E, Cipla or Lupin?
Lupin has the lower P/E: Cipla trades at 38.8 and Lupin at 17.4.
Which gave better returns in the last year, Cipla or Lupin?
Lupin did better: Cipla returned -7.4% and Lupin returned -0.8% over one year.
What is the difference between Cipla and Lupin?
Both are NSE-listed companies in Healthcare. Cipla is about 1.2 times the size of Lupin by market cap. In the latest financial year Cipla reported revenue of ₹28,163 Cr and Lupin ₹27,958 Cr. Operating margin is 17.0% for Cipla and 30.1% for Lupin. Debt to equity is 0.01 for Cipla and 0.23 for Lupin.
Which is better, Cipla or Lupin?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Cipla leads on 7 and Lupin on 11. Cipla is ahead on valuation, financial health and technicals. Lupin is ahead on size, profitability and growth. On StoxGud's rules-based checklist Cipla scores 7/10 and Lupin scores 6/10. This is information, not advice: consult a SEBI-registered adviser before investing.